The company plans to offer testosterone replacement therapy, marking its first foray into prescribing controlled substances.
Hims & Hers Health, Inc. (NYSE: HIMS), the leading global health and wellness platform, today announced the launch of new ...
Hims & Hers Health ( NYSE:HIMS ), the health and wellness platform, launched injectable and oral testosterone replacement therapies for eligible men. Hims & Hers shares rose 0.51% in premarket.
Well, have no fear, telehealth giant Hims is here to capitalize on…er, help address your feelings of inadequacy by offering testosterone replacement therapy service. The company announced Wednesday ...
Stocktwits on MSN
HIMS stock gains as company enters German men’s weight market as investors watch US peptide compounding policy
The new launch builds on the company’s earlier efforts at expanding in Europe, including the acquisition of UK-based health ...
Hims & Hers stock jumps as HHS reviews policy letting compounding pharmacies make peptides like BPC-157. Read more here.
Hims & Hers Health (HIMS) is positioned as a dominant DTC Telehealth platform leveraging GLP-1s to create frictionless, ...
Suppose improving growth and profitability allow investors to value the company at 2.5x expected 2027 sales. Applying that multiple to the $3.99 billion revenue estimate produces a market ...
Shares of Hims & Hers Health HIMS rose 5% on Tuesday after the telehealth company launched an online weight-management ...
Hims & Hers Health, Inc. announced the launch of new injectable and oral testosterone replacement therapies (TRT) for eligible men. It?s the largest expansion of the company?s men?s health program ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results